Cargando…
Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes mellitus. In clinical trials, significant reductions in serum glucose and weight were demonstrated for exenatide with primary glycemic effects of the twice daily formulation on prandial glucose control. In this paper, we revie...
Autores principales: | Odegard, Peggy Soule, DeSantis, Anthony |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048016/ https://www.ncbi.nlm.nih.gov/pubmed/21437127 |
Ejemplares similares
-
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
por: Raman, Vandana S., et al.
Publicado: (2010) -
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
por: Robles, Gisela I, et al.
Publicado: (2009) -
Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010) -
Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
por: Schnabel, Catherine A, et al.
Publicado: (2006) -
Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)